524516 BACPHAR

Bacil Pharma Share Price

₹43.44 -0.88 (-1.99%)

23 Nov, 2024 15:53

SIP TrendupStart SIP in BACPHAR

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 12.19%
  • Over 3 Month + 175.63%
  • Over 6 Month + 106.37%
  • Over 1 Year + 636.27%
SIP Lightning

Smart Investing Starts Here Start SIP with Bacil Pharma for Steady Growth!

Invest Now

Bacil Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Bacil Pharma Financials

Bacil Pharma Technicals

EMA & SMA

Current Price
₹43.44
-0.88 (-1.99%)
pointer
  • stock-down_img
  • Bullish Moving Average 9
  • stock-up_img
  • Bearish Moving Average 7
  • 20 Day
  • ₹44.02
  • 50 Day
  • ₹37.45
  • 100 Day
  • ₹30.99
  • 200 Day
  • ₹24.31

Resistance and Support

43.44 Pivot Speed
  • R3 43.44
  • R2 43.44
  • R1 43.44
  • S1 43.44
  • S2 43.44
  • S3 43.44

What's your outlook on Bacil Pharma?

You can only vote for once

Bacil Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-23 Quarterly Results
2024-10-15 Others
2024-09-27 Increase in Authorised Capital
2024-08-14 Quarterly Results
2024-05-21 Audited Results

Bacil Pharma F&O

Bacil Pharma Shareholding Pattern

No data available.

About Bacil Pharma

  • NSE Symbol
  • BACPHAR
  • BSE Symbol
  • 524516
  • ISIN
  • INE711D01018

Similar Stocks to Bacil Pharma

Bacil Pharma FAQs

Bacil Pharma share price is ₹43 As on 23 November, 2024 | 15:39

The Market Cap of Bacil Pharma is ₹25.6 Cr As on 23 November, 2024 | 15:39

The P/E ratio of Bacil Pharma is 66.4 As on 23 November, 2024 | 15:39

The PB ratio of Bacil Pharma is 23.4 As on 23 November, 2024 | 15:39

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23